Abbott Laboratories (NYSE: ABT) is trading down in premarket on Wednesday even though it reported solid results for its fiscal fourth quarter.Why is Abbott stock down on Wednesday?Copy link to sectionInvestors seem unhappy also because the healthcare company issued a not-so encouraging guidance for the future. Abbott now forecasts its sales to climb up to 10% (excluding COVID sales) on $4.50 to $4.70 of per-share earnings in fiscal 2024. Analysts, in comparison, had called for $4.63 a share. Robert Ford – i ...

Why bother talking about safe-haven stocks for a recession when we already dodged that bullet last year? Tell me you haven’t seen a Friday the 13th movie without telling me. Any horror film aficionado knows that if you ever survive the maniacal clutches of Jason Voorhees, it ain’t over until the credits roll. Till then, you should probably avoid any bodies of water.It’s the same principle with so-called recession stocks. No one’s hoping for an economic downturn – I think we’ve all had our fair share of dram ...

Several expansive companies are expected to post stellar quarterly growth when they report Q4 earnings on Wednesday, January 24.Having a dominant presence in their respective markets here are a few top-rated Zacks stocks to consider as their quarterly results approach.The Progressive (PGR) : Home and auto insurance giant Progressive shouldn’t be overlooked ahead of its Q4 results with earnings projected to soar 58% to $2.38 per share versus $1.50 a share in the comparative quarter. Fourth quarter sales are ...

Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories (ABT) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Abbott Laboratories is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pr ...

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.19 per share, indicating an increase of 15.5% compared to the year-ago period. Analysts forecast revenues of $10.17 billion, representing an increase of 0.8% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.7% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company ...

Abbott's Volt™ Pulsed Field Ablation System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to target and treat tissue in the heart Abbott's Volt PFA System is designed to overcome limitations of first-generation PFA systems by providing physicians a clearer indication of contact between the Volt PFA Catheter and targeted tiss ...

Abbott’s (ABT) Established Pharmaceuticals Division (EPD) businesses are expected to grow in the coming quarters, banking on new launches. However, the business environment continues to be challenging globally. The stock carries a Zacks Rank #3 (Hold) currently.Abbott is expanding its Diagnostics business foothold (consisting of 24% of the company’s total revenues in the third quarter of 2023). Over the past few quarters, there has been a decline in demand for Abbott’s rapid diagnostic tests to detect COVID ...

Abbott Laboratories (ABT) is slated to report its fourth-quarter 2023 results on Jan 24 before market open.The company posted adjusted earnings per share (EPS) of $1.14 in the last reported quarter, which topped the Zacks Consensus Estimate by 3.64%. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all occasions, the average beat being 6.76%.Let's see how things have shaped up prior to this announcement.Factors at PlayEstablished Pharmaceuticals Similar to the last report ...

2024年1月8日至11日，第42届摩根大通医疗健康年会（J.P. Morgan Healthcare Conference，以下简称JPM）在美国加利福尼亚州旧金山隆重召开。JPM大会是全球生物医药健康领域规模最大的行业盛会，也是全球信息量最大的医疗投资、产业交流合作大会，涵盖了整个全球医疗保健领域，包括制药公司、医疗保健服务提供商、营利和非营利组织以及医疗器械公司。 雅培方面，对话摩根大通医疗技术分析师的是公司董事长兼首席执行官Robert Ford。 Robert Ford 业绩概览 Robert表示，雅培有一个野心勃勃的目标，那就是超出自己目前水平的50%，到2030年帮助改善30亿人的生活。雅培的故事源于19世纪末，自那以来，雅培一直在现代医疗领域取得突破性创新，是仅有的49家始终存在于《财富》500强榜单中的公司之一。 目前，雅培在全球的员工超过115,000名，服务于160多个国家。公司以一系列知名的品牌建立了良好形象，这些品牌年销售额超过400亿美元，在过去10年翻了一番。雅培的构成多年来发生了变化，但不变的是雅培致力于为股东带来长期价值的框架。雅培有意在投资组合、不同的地理位置和不同类型的 ...

Abbott (ABT) closed at $113.92 in the latest trading session, marking a +0.37% move from the prior day. This change outpaced the S&P 500's 0.08% gain on the day. Meanwhile, the Dow lost 0.31%, and the Nasdaq, a tech-heavy index, added 0.02%.Heading into today, shares of the maker of infant formula, medical devices and drugs had gained 4.51% over the past month, lagging the Medical sector's gain of 6.57% and outpacing the S&P 500's gain of 3.52% in that time.Market participants will be closely following the ...